MentionFox
Home › Who owns › enGene Therapeutics Inc.
Owners, funding and legal record

Who owns enGene Therapeutics Inc.? Owners, funding and legal record

Before you sign with, sell to or invest in enGene Therapeutics Inc.

MentionFox check on enGene Therapeutics Inc.: no red flags found in 16 sources; 1 item to note (checked 15 November 2026). mentionfox.com/c/who-owns/engene-therapeutics

  • Note: Layoff plan disclosed Jun 2026 (filing)

Check enGene Therapeutics Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about enGene Therapeutics Inc.?

enGene Therapeutics Inc. is a publicly traded company (Nasdaq: ENGN). The most recent 5%+ ownership report names Eventide Asset Management, LLC holding 5.1% (Schedule 13G, filed 2026-11-13).

As of November 15, 2026, enGene Therapeutics Inc. is a publicly traded company (Nasdaq: ENGN); its largest reported holder is Perceptive Advisors, with 9.99% on Schedule 13G/A of August 14, 2026, then BML Investment Partners, L.P. (9.95%). The largest insider holding is Forbion Growth Management B.V., a 10% owner, with 6,798,362 shares (10.1% of shares outstanding), per Form 4 of November 1, 2024 (Schedule 13G/A, August 14, 2026).

ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies ↓

Is this your company?

About to sign with, pay or invest in enGene Therapeutics Inc.? See the free Snapshot first.

Watch enGene Therapeutics Inc.

Free to see. No signup.

Is enGene Therapeutics Inc. a real, registered company?

Before you sign or pay

Who are enGene Therapeutics Inc.'s owners and officers?

enGene Therapeutics Inc.: industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-11-13).

ReportHolderShare
Schedule 13G, 2026-11-13Eventide Asset Management, LLC5.1%
Schedule 13G/A, 2026-08-14Perceptive Advisors LLC9.99%
Schedule 13G/A, 2026-08-14Deep Track Capital, LP0%
Schedule 13G/A, 2026-08-14Venrock Healthcare Capital Partners Iii, L.P.0%
Schedule 13G/A, 2026-08-13Raymond Debbane9.3%
Schedule 13G/A, 2026-08-12Blue Owl Capital Holdings LP0.76%
Schedule 13G, 2026-07-22Anders Hove5%
Schedule 13G/A, 2026-05-15Cormorant Asset Management, LP0%
Schedule 13G/A, 2026-05-14Bml Investment Partners, L.P.9.95%
Schedule 13G, 2026-05-13Bml Investment Partners, L.P.7.8%
Schedule 13G/A, 2026-05-05Raymond Debbane7.8%
Schedule 13G, 2026-02-17Cormorant Asset Management, LP5.97%

Questions about who owns enGene Therapeutics Inc.

Who owns enGene Therapeutics Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of enGene Therapeutics Inc.: Perceptive Advisors LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Bml Investment Partners, L.P. (9.95%, Schedule 13G/A, filed 2026-05-14), Raymond Debbane (9.3%, Schedule 13G/A, filed 2026-08-13), Eventide Asset Management, LLC (5.1%, Schedule 13G, filed 2026-11-13) and Anders Hove (5%, Schedule 13G, filed 2026-07-22).

Who are the largest shareholders of enGene Therapeutics Inc.?

By the share each holder's latest filing reports, the largest holders of enGene Therapeutics Inc. on this page are Perceptive Advisors LLC (9.99%), Bml Investment Partners, L.P. (9.95%) and Raymond Debbane (9.3%).

When did Perceptive Advisors LLC buy into enGene Therapeutics Inc.?

The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G/A, filed 2026-08-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Want the whole picture on enGene Therapeutics Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on enGene Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on enGene Therapeutics Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    20 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.
FiledPersonRoleChangeEffective
Form 8-K, 2026-07-16Richard GlickmanDirectordeparted
Form 8-K, 2026-06-15Hussein SweitiChief Medical Officerdeparted2026-06-14

Which insiders own enGene Therapeutics Inc. shares?

Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.

Shares outstanding: 67,016,316 as of 2026-09-02, from the company's latest SEC cover page.

How much has enGene Therapeutics Inc. raised?

No fundraising or offering filing from enGene Therapeutics Inc. is on file with us.

Red flags found

2 exit or restructuring plans on Form 8-K (latest Form 8-K, 2026-06-18).

Keep reading

More on enGene Therapeutics Inc. and the records around it.

enGene Therapeutics Inc. elsewhere on the record

Companies that share a holder

Related pages

Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.

Not for employment, credit, insurance or tenancy decisions.

Cite this page

Permanent URL: https://mentionfox.com/who-owns/engene-therapeutics
Last updated 2026-11-15
Who owns enGene Therapeutics? Publicly traded (Nasdaq: ENGN). MentionFox, 2026-11-15. https://mentionfox.com/who-owns/engene-therapeutics